Module contents

Module home
Module introduction
Module information
About the author

Learning notes

Pre-module test

 

Section 1: Treatment of antidepressant-induced sexual dysfunction

(1.1) Section 1: Treatment of antidepressant-induced sexual dysfunction

(1.2) Before you begin

(1.3) Clinical vignette: a woman who thought she was 'frigid'

(1.4) Comment: a woman who thought she was 'frigid'

(1.5) Reflection

(1.6) Suggested answers

(1.7) Reflection

(1.8) Suggested answers

(1.9) Overview of treatment strategies

(1.10) Modification of the current antidepressive treatment

(1.11) Treatment of sexual dysfunction targeting specific receptors

(1.12) Other treatments

(1.13) Reflection

(1.14) Pharmacological reversal: target noradrenaline

(1.15) Interactive exercise: outlook: autoreceptors

(1.16) Reflection

(1.17) Pharmacological reversal: target serotonin

(1.18) Reflection

(1.19) Pharmacological reversal: target dopamine

(1.20) Reflection

(1.21) Pharmacological reversal: other targets

(1.22) Pharmacological reversal: target nitric oxide (NO)

(1.23) Phosphodiesterase5 (PD5)-inhibitors head to head

(1.24) Phosphodiesterase5 (PD5)-inhibitors

(1.25) It all starts with nitric oxide…

(1.26) PD5-inhibitors: contraindications and warnings - what your patient should know

(1.27) Yet another story...

(1.28) Alprostadil

(1.29) Female sexual dysfunctions: licensed pharmacological treatments

(1.30) Female sexual dysfuction: drugs that remain controversial

(1.31) Section 1: Recap

(1.32) Section 1: Summary

 

Section 2: Other treatments for sexual dysfunction

(2.1) Section 2: Other treatments for sexual dysfunction

(2.2) Reflection

(2.3) Suggested answers

(2.4) Hormone treatments for women

(2.5) Why has HRT fallen out of favour with women?

(2.6) HRT: what does it mean for the individual patient?

(2.7) Hormone treatments for women - potential adverse effects

(2.8) Reflection

(2.9) Suggested answers

(2.10) Hormone treatments for men

(2.11) Outlook

(2.12) Reflection

(2.13) Suggested answers

(2.14) Complementary medicines for sexual dysfunction

(2.15) Recommending complementary medicines: issues

(2.16) Hypomanic episodes

(2.17) Outlook

(2.18) Section 2: Recap

(2.19) Section 2: Summary

 

Section 3: Formal aspects of prescribing for sexual dysfunction

(3.1) Section 3: Formal aspects of prescribing for sexual dysfunction

(3.2) Prescribing unlicensed medications: recommendations

(3.3) The GMC requirements for prescribing unlicensed medications

(3.4) Informed consent

(3.5) The criteria for informed consent: quick recap

(3.6) Reimbursement for treatments

(3.7) The BNF requirements for prescribing for erectile dysfunction

(3.8) The severe distress clause

(3.9) Section 3: Recap

(3.10) Section 3: Summary

 

Module summary

Module test

Acknowledgements

Send feedback

 

Useful resources

Take-home notes

References

Further reading

© 2019 Royal College of Psychiatrists